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Background: The α2-adrenoceptor agonist xylazine as an anesthetic has been widely used either alone or in
combination with other anesthetics, such as ketamine, in veterinary clinic and research. In the last decade xylazine
has been used in drug abusers in certain geographic area. This study investigated the effects of xylazine on blood
glucose level and insulin secretion in normoglycemic and insulin-dependent diabetic monkeys.
Methods: Both adult cynomolgus (n = 10) and rhesus (n = 8) monkeys with either sex were used in the study.
Xylazine (1–2 mg/kg) was administrated intramuscularly. Blood glucose, insulin, glucagon and glucagon-like peptide
1 in overnight-fasted monkeys were measured immediately before and after xylazine administration. The
hyperinsulinemic-euglycemic clamp method was used in the study for assessing the potential mechanism of
xylazine-induced hyperglycemia.
Results: Xylazine administration increased the blood glucose levels from 58 ± 3 to 108 ± 12 mg/dL in
normoglycemic (n = 5, p < 0.01) and from 158 ± 9 to 221 ± 13 mg/dL in insulin-dependent diabetic (n = 5, p < 0.01)
monkeys and was not accompanied by any significant changes in blood insulin, glucagon, and glucagon-like
peptide-1. Xylazine-induced hyperglycemia occurred within 10 min and reached the peak at 35 min after injection.
Xylazine-induced hyperglycemia declined slowly in diabetic animals. The α2-adrenoceptor antagonist yohimbine
was administrated to bring down the elevated glucose level to the pre-xylazine one in 4 out of 5 diabetic animals.
To assess the potential mechanism, the hyperinsulinemic-euglycemic clamp was used to maintain a nearly
saturated and constant insulin level for minimizing endogenous insulin glucoregulation. Xylazine administration
decreased glucose infusion rate, from 14.3 ± 1.4 to 8.3 ± 0.8 mg/min/kg (n = 6, p < 0.01) in normoglycemic rhesus
monkeys, which indicates that the glucose metabolic rate (M rate) was decreased by xylazine. In addition, after
clamping blood glucose level in a range of 55 to 75 mg/dL for 40 min with constant glucose infusion, xylazine
administration still increased blood glucose concentration.
Conclusions: We conclude that xylazine administration induces hyperglycemia in normoglycemic and insulin-
dependent diabetic monkeys potentially via stimulation of α2-adrenoceptors and then reducing tissue sensitivity to
insulin and glucose uptake.
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Xylazine is an α2-adrenoceptor agonist and shares the
similar pharmacological properties with clonidine [1-4]. It
has been widely used as a drug for sedation and analgesia
in veterinary clinic and non-human mammal research for
several decades [5,6]. It can relieve pain and relax skeletal
muscle. Xylazine is often co-administrated with ketamine
to provide reliable anesthesia effects [7,8]. The sedative
and muscle-relaxing properties of xylazine can be benefi-
cial in reducing ketamine-induced side effects, such as
tremor and muscle rigidity. It also can reduce animal gas-
tric and intestinal motility during gastrointestinal surgery
or endoscopy. Its analgesic action is less than 30 min, but
its sedative effect can last 2 hrs. Xylazine has adverse
effects (e.g., cardiac conduction disturbances, bradycardia,
and myocardial depression) similar to other α2 agonists.
These adverse effects can be attenuated, blocked or re-
versed by adrenergic α2-receptor antagonists such as
yohimbine [9,10].
Maintaining blood glucose homeostasis involves com-
plex neurohumoral regulation. Stress can increase blood
glucose by changing several hormones including insulin,
glucagon, GLP-1, and catecholamines [11,12]. Adminis-
tration of the potent α2 agonist xylazine can result in a
neurohumoral imbalance which affects blood glucose.
In fact, several studies demonstrate that administration
of xylazine increases blood glucose in various animal
species, including dogs, cats, rats, and mice [12-16].
Currently, xylazine is not authorized for human use.
However, early studies showed that xylazine induced
sedation, muscle relaxation, and analgesia in healthy vol-
unteers [17,18]. All volunteers in those studies exhibited
a significant reduction of blood pressure and heart rate.
Interestingly, xylazine effectively lowered blood pressure
and heart rate in some hypertensive patients [18,19].
This veterinary anesthetic compound has been used as a
new recreational drug among drug abusers in certain
geographic areas [20-24]. Chronic use of this substance
induces physical dependence and open skin ulcers or ab-
scesses [25]. More severe intoxication has been reported
in xylazine users [19] and post-mortem examinations
have attributed the death to xylazine (26–29). Medical
examination in some drug-related deaths detected xylazine
concurrently [26-29].
Previous studies show that xylazine increases blood
glucose in both small and large animals [12-14]. How-
ever, the effects of this drug on blood glucose homeo-
stasis in non-human primates (NHPs) are unclear. TheTable 1 Characteristics of the diabetic and normoglycemic cy
Monkey n Age (year) Body weight (kg)
Normal 5 6.8 ± 0.3 6.7 ± 0.7
Diabetic 5 18.3 ± 0.8*** 6.0 ± 0.7
Values are expressed as the mean ± SEM. Normal, normoglycemic monkeys; Diabetpresent study investigates the effects of xylazine on
blood glucose in fasted, ketamine-anesthetized monkeys
with or without diabetes. We also assessed xylazine’s
effects on the secretion of insulin, glucagon, and glucagon-
like peptide 1 (GLP-1). Understanding xylazine pharma-
cology and adverse effects in NHPs can provide useful
information regarding its use in veterinary clinics and
animal research as well as for proper therapy of abusers
intoxicated with this α2-adrenoceptor agonist.
Methods
Animal care and procedures
Experiments were carried out in cynomolgus (Table 1)
and rhesus monkeys of either sex. These monkeys were
individually housed and maintained in our animal facility
in accordance with guidelines approved by the Association
for Assessment and Accreditation of Laboratory Animal
Care (AAALAC). Animals had continuous access to
water ad libitum and controlled access to food. Room
temperature was maintained at ∼ 21°C. The animals
were maintained on a 12 hr light/dark cycle with lights
off from 6 PM to 6 AM. The monkeys were maintained
with a complete nutritionally balanced diet (Shanghai
Shilin Biotechnology, Inc., Shanghai, China) and enriched
with seasonal fruits and vegetables. The experimental
protocol was approved by the Institutional Animal Care
and Use Committee (IACUC) of Crown Bioscience, Inc.
On the experimental day each monkey was fasted over-
night and received ketamine (10 mg/kg, Fujian Gutian
Pharmaceutical Co. Ltd., Fujian, China) intramuscular ad-
ministration. Sedation was maintained with additional
ketamine (5 mg/kg) injection as needed. Xylazine and yo-
himbine (Sigma-Aldrich Co., St. Louis, MO, USA) were
given intramuscularly for testing their effects on blood
glucose. Body temperature was maintained during each
experiment at ~37°C by a thermostatically controlled
warm water–circulating pad placed beneath the body.
Food and water were provided again after experimental
animals were returned to their cages and fully recovered
from anesthesia.
Blood collection and handling
Whole blood samples (1–2 ml/per time) at various time
points after anesthesia or compound treatment were
collected from a plastic needle inserted into an arm
vein. Samples were collected into an EDTA-washed
(0.5 M EDTA, pH 8.0, Gibco, Invitrogen Corporation,
Grand Island, NY, USA) 2.5-mL disposable syringe andnomolgus monkeys used
Fasting glucose (mg/dL) Fasting insulin (μIU/ml)
47.9 ± 5.4 23.9 ± 3.9
183.6 ± 29.8*** 12.1 ± 0.7***
ic, insulin-dependent diabetic monkeys; ***, p < 0.001; vs. normal.
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collection tube containing 7.5 mg EDTA (Sherwood
Medical, St. Louis, MO, USA). The collection tube also
contained aprotinin (Sigma-Aldrich Co., St. Louis, MO,
USA) for reduction of protein degradation and DPP IV
inhibitor (EMD Millipore Corporation, Billerica, MA,
USA) for prevention of GLP-1 degradation. Blood sam-
ples were centrifuged within 30 min at 4°C, 3000 g for
10 min and then the plasma was separated following
standard protocols established in our laboratory. The
plasma samples were kept in a freezer at −80°C prior
to analysis of glucose, insulin, glucagon, and GLP-1
concentrations.
Intravenous glucose tolerance test (ivGTT)
To evaluate the β-cell function ivGTT was performed in
the diabetic and normoglycemic monkeys according to
the method reported previously [30,31]. The animals were
fasted for 16 hrs and anesthetized with an initial dose of
ketamine at 15 mg/kg (i.m.) with additional doses during
the procedure if needed. The cephalic and/or saphenous
veins were cannulated separately for glucose infusion and
blood collection. Glucose (0.25 g/kg = 0.5 ml/kg of 50%
dextrose) was intravenously infused during 30 sec and the
system was flushed with 5 ml heparinized saline to remove
residual glucose. Blood was collected immediately before
and at 3, 5, 7, 10, 15, 20, 30 min after glucose infusion.
Blood samples were immediately transferred to heparin-
ized and chilled tubes on ice. Plasma was then separated
and stored at −80°C for subsequent assays.
Hyperinsulinemic-euglycemic clamp
Hyperinsulinemic-euglycemic clamp analysis was performed
in 16-hr-fasted monkeys under ketamine-anesthesia.
Cannulation of the cephalic and/or saphenous veins was
conducted for insulin and glucose infusion, and blood
drawing for glucose measurement. Insulin (biosynthetic
human insulin, Novo Nordisk, Denmark) was diluted
to 300 mU/ml by isotonic saline to which 2 ml of the
subject’s blood per 50 ml was added in order to avoid
adhesion of insulin to the syringe plastic surface. Insulin
infusion at various rates was given during the 1st 10 min
to quickly adjust blood glucose near a targeted level. The
infusion rate for the hyperinsulinemic-euglycemic clamp
was then maintained at 40 mU/m2 Surface Area*min as
reported previously [32].
A variable amount of 20% D-glucose was intraven-
ously infused to maintain blood glucose. Blood samples
were taken every 5 min and glucose was measured by a
glucose analyzer (Accu-Chek Active, Roche Diagnostics,
Indianapolis, IN, USA) to allow adjustment of the glu-
cose infusion rate accordingly. In the 1st set of experi-
ments, when blood glucose was adjusted and balanced
for approximately 120 to 150 min and then for a 40-minstable period of glucose levels clamped in a range of 55
to 75 mg/dL under constant infusion of glucose, xylazine
was injected intramuscularly. Blood glucose concentration
was monitored for another 30 to 40 min after xylazine
injection. In the 2nd set of experiments, xylazine was
injected after blood glucose level was adjusted for 95 to
135 min and then maintained in the range of 55 to
75 mg/dL for 40 min. The glucose infusion rate was ad-
justed after xylazine treatment to clamp blood glucose
in the range of 55–75 mg/dL. The difference of the
glucose metabolic rates (M rate) was calculated from the
glucose infusion rates before and after xylazine treatment.
Data analysis
Data were expressed as mean ± SEM. Statistical significance
for multiple observation parameters in the same group was
determined by One-way Analysis of Variance (ANOVA). If
statistical significance of differences was detected, then
Tukey’s Multiple Comparison Test (GraphPad Software,
Inc., La Jolla, CA, USA) was also conducted. The compari-
son between diabetic and normoglycemic groups was tested
by the un-paired t-test. Statistical significance was consid-
ered if p value was <0.05.
Results
Selection of diabetic monkeys
As the effects of xylazine on blood glucose had not been
studied in NHPs previously, we selected diabetic and
normoglycemic monkeys for this study. Based on blood
glucose (<90 mg/dL) and other biochemistry tests, five
healthy young cynomolgus monkeys were selected for
the normoglycemic group (Table 1). The other five
cynomolgus monkeys were selected from spontaneously
naturally developed and already insulin-treated diabetic
animals with blood glucose >150 mg/dL. Compared with
controls, the diabetic animals were significantly older
(Table 1). They received insulin treatment daily because
of their high blood glucose, low insulin, and losing body
weight if not insulin-treated.
The selected animals were characterized by intravenous
glucose tolerance test (ivGTT) and insulin secretion assay.
Figure 1A shows that blood glucose and insulin were sig-
nificantly increased immediately after glucose challenge in
normoglycemic monkeys who had normal β-cell function.
The significant increase in blood glucose lasted 20 min
and 15 min in insulin and then returned to the control
levels within 30 min. However, in the insulin-dependent
diabetic monkeys only blood glucose was significantly in-
creased without significant alteration of insulin (Figure 1B).
The glucose AUC (area under the curve) was significantly
higher in the diabetic monkeys than in the normoglycemic
ones (Figure 1C, p < 0.01). In contrast, the insulin AUC
was significantly lower in the diabetic monkeys than in the







Figure 1 Intravenous glucose tolerance test (ivGTT) in normoglycemic and insulin-dependent diabetic cynomolgus monkeys (Table 1).
Plasma glucose and insulin levels were measured at the scheduled time points in normoglycemic (panel A, n = 5) and insulin-dependent diabetic
(panel B, n = 5) monkeys. Panel C shows the glucose AUCs of the ivGTTs for the nomorglycemic (blank bar) and diabetic (strip bar) monkeys.
Panel D shows the insulin AUCs of the ivGTTs for the normoglycemic (blank bar) and diabetic (strip bar) monkeys. *, p < 0.05; **, p < 0.01,
***, p < 0.001; vs. the level at time zero or vs. the normoglycemic group.
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normoglycemic monkeys and was significantly impaired
in the diabetic ones. To look at the differences between
the strains and their xylazine responses, eight normal
rhesus monkeys were also used for xylazine test during
glucose clamp.
Xylazine-induced hyperglycemia in diabetic and
normoglycemic monkeys
After verification of the pancreatic functions in the se-
lected diabetic and normoglycemic monkeys, the effects of
xylazine on blood glucose were investigated. Blood glucose
was measured immediately before and at various time
points over the 2 hr observation (Figure 2A). Intramuscular
injection of xylazine (1–2 mg/kg) significantly increased
blood glucose in a time-dependent manner in the normo-
glycemic monkeys (Figure 2A, open circle). An initial rise
of blood glucose was observed at 5 to 10 min after xylazine
injection. The increase reached the peak of 108 ± 12 mg/dL
from the baseline of 58 ± 3 mg/dL (p < 0.01) at approxi-
mately 35 min following xylazine administration. Hypergly-
cemia began to decline approximately 45 min after xylazine
injection. Blood glucose in all of the normoglycemic mon-
keys gradually returned to the pre-xylazine levels within
2 hrs (Figure 2A, open cycle).Xylazine-induced hyperglycemia was also observed in
the diabetic monkeys (n = 5). Xylazine administration
(1–2 mg/kg) increased blood glucose from the baseline
of 158 ± 9 mg/dL to 221 ± 13 mg/dL at approximately
35 min following the injection (p < 0.05, Figure 2A, filled
cycle). The initial rise and time to the peak after xylazine
administration were very similar to those observed in
the normoglycemic monkeys. However, the initial decline
of blood glucose was delayed to approximately 60 min
after xylazine administration. The decline toward the pre-
xylazine level was much slower in the diabetic monkeys
than in the normoglycemic ones (Figure 2A, dot line).
Blood glucose remained high 2 hrs after xylazine adminis-
tration (Figure 2A, filled circle). Only one out of 5 diabetic
monkeys gradually returned to the pre-xylazine glucose
level at 2 hr after xylazine administration. The other
diabetic animals retained their elevated glucose levels
2 hrs after xylazine injection and the α2-adrenoceptor
antagonist yohimbine (1–4 mg/kg) was injected to
restore blood glucose toward the pre-xylazine levels for
safety reason.
Effects of xylazine on glucoregulatory hormones
To assess the possible mechanism of xylazine-induced




Figure 2 Hyperglycemic effects of xylazine in fasted, ketamine-
anesthetized cynomolgus monkeys. Panel A shows the time-
dependent effects of xylazine in normoglycemic (open circle, n = 5)
and insulin-dependent diabetic (solid circle, n = 5) monkeys. The
dotted lines show the pre-xylazine glucose levels in normoglycemic
and insulin-dependent diabetic monkeys. The time-dependent
effects of xylazine on plasma insulin and glucagon are shown in panel
B and C, respectively. ↑, the time point that xylazine (1–2 mg/kg) was
injected intramuscularly. **, p < 0.01; vs. the baseline level at time zero.
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As shown in Figure 2B (open cycles), the baseline level of
plasma insulin in the normoglycemic monkeys was 15.1 ±
8.3 μIU/ml (n = 3). Xylazine administration (1–2 mg/kg)
did not cause statistically significant alterations of plasma
insulin in the non-diabetic monkeys (p > 0.05). Compared
to the non-diabetes, the plasma insulin level was relatively
lower in the diabetic monkeys (11.2 ± 4.8 μIU/ml, n = 5)
and remained unchanged during 90-min observation after
xylazine administration (Figure 2B, solid cycle).
The mean plasma glucagon levels were 0.47 ± 0.10 nM
(n = 3) for the normoglycemic and 0.51 ± 0.02 nM (n = 5)for the insulin-dependent diabetic monkeys. Xylazine
administration (1–2 mg/kg) did not alter the levels of
plasma glucagon in either group (Figure 2C, p > 0.05). In
addition, xylazine had no statistically significant effects
on plasma GLP-1 level in both diabetic and normogly-
cemic monkeys. The baseline plasma GLP-1 level was
1.32 ± 0.14 pM (n = 3) for the normoglycemic monkeys
and 2.52 ± 0.95 pM (n = 5) for the diabetic ones. The
plasma GLP-1 level was 1.50 ± 0.64 pM for the normo-
glycemic monkeys and 2.43 ± 1.39 pM for the diabetic
animals at 30 min after xylazine injection.
Effects of xylazine on blood glucose during
hyperinsulinemic-euglycemic clamp
To exclude or minimize the influence of endogenous
insulin on xylazine-induced hyperglycemia and also to
see the effects of xylazine on blood glucose in another
monkey strain (rhesus), the hyperinsulinemic-euglycemic
clamp was performed in normoglycemic rhesus monkeys
of either sex (n = 8). Their mean age was 10.7 ± 1.1 years
with the body weight of 7.7 ± 0.8 kg. Compared with the
normoglycemic cynomolgus monkeys (Table 1, 47.9 ±
5.4 mg/dL), their blood glucose was significantly higher
(86 ± 4.6 mg/dL) probably due to their older ages. They
were intravenously infused with a constant dose of insu-
lin following an initial bolus infusion in the 1st 10 min
(Figure 3, open square). Glucose was simultaneously
infused with rates adjusted until blood glucose was
maintained in a range of 55 to 75 mg/dL under a con-
stant infusion rate (Figure 3, open triangle). Prior to
xylazine injection, a 40 min period (from 150–190 min
after the initiation of the clamp, Figure 3) of stable
blood glucose ranging from 55 to 75 mg/dL was reached
(Figure 3). Administration of xylazine (2 mg/kg) signifi-
cantly increased blood glucose level, from 55 mg/dL
(left panel) and 64 mg/dL (right panel) for pre-xylazine
to the peak of 83 mg/dL (left panel) and 99 mg/dL (right
panel), respectively, despite the glucose infusion rate be-
ing unchanged. These results indicate that xylazine still
produced hyperglycemia in the presence of clamp-
maintained hyperinsulinemia which maximally inhibited
endogenous negligible insulin secretion.
To further investigate the role of insulin in xylazine-
induced hyperglycemia, another set of experiments was
conducted in normoglycemic monkeys who were clamped
for maintaining hyperinsulinemia to minimize endogenous
insulin glucoregulation. When blood glucose in these
animals reached 40-min stabilization in a range of 55 to
75 mg/dL under constant glucose infusion, xylazine
(2 mg/kg) was intramuscularly administrated. In order
to hold the blood glucose level in the constant range of
55 to 75 mg/dL by the negative feedback principle, the
glucose infusion rate was significantly reduced, from
14.3 ± 1.4 mg/min/kg for pre-xylazine (Figure 4, open
µµ
Figure 3 Effects of xylazine on blood glucose concentrations in two fasted normoglycemic rhesus monkeys during the
hyperinsulinemic-euglycemic clamp. Insulin was given with an initial bolus infusion to reduce blood glucose close to a targeted level followed
by a constant infusion rate of 40 mU/m2 Surface Area*min (open squares) for maintaining hyperinsulinemia. Glucose was infused simultaneously
with adjustable rates to clamp blood glucose in the euglycemic range of 55 – 75 mg/dL (open triangles). Xylazine (2 mg/kg) was injected
intramuscularly after 40-min euglycemia stabilization to observe its effects on blood glucose when glucose was infused at a constant rate.
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striped bar, n = 6, p < 0.01). Under these steady-state
conditions of normoglycemia, the glucose infusion rate
equals glucose uptake of the body and is therefore a
measure of tissue sensitivity to exogenous insulin. These
results support our hypothesis that xylazine-induced
hyperglycemia most likely resulted from a reduction of
tissue sensitivity to insulin, because blood insulin was
stably maintained at a high level by a constant infusion.Figure 4 Effects of xylazine on the glucose metabolic rate in
fasted normoglycemic rhesus monkeys. Hyperinsulinemia was
maintained by insulin infusion at a constant rate of 40 mU/m2
Surface Area*min. Glucose was infused simultaneously to adjust and
balance blood glucose for a period of 95 ± 11 min and then to
achieve euglycemia (55 – 75 mg/dL) stably for 40 min with a
constant infusion rate. Xylazine (2 mg/kg) was then injected
intramuscularly. To hold blood glucose concentration constantly in
the pre-xylazine range (55 – 75 mg/dL), the glucose infusion rate
was decreased during next 40 min after xylazine administration. The
glucose infusion rates were calculated as the glucose metabolic
rates (M rates) at the times before (Pre-xylazine) and after (Xylazine)
xylazine administration. **, p < 0.01; vs. Pre-xylazine.Discussion
The main finding of this study is that xylazine administra-
tion produced an acute hyperglycemia without significant
changes in blood insulin, glucagon, and GLP-1 in both
insulin-dependent diabetic and normoglycemic monkeys.
As xylazine is widely used either alone or combined with
other anesthetics, such as ketamine, in various animal re-
search, its hyperglycemia can have an obvious impact on
experimental results, especially in diabetic and metabolic
research. Xylazine is commonly used as an anesthetic and
analgesic in veterinary clinics [5,6]. Also, due to increasing
amongst drug abusers [20-22], xylazine-induced hypergly-
cemia potentially becomes a clinically relevant issue, espe-
cially in diabetic subjects.
Xylazine-induced hyperglycemia was reported previ-
ously in various species, including dogs [11], cattle
[33,34], and rats [12,35]. However, these studies were
performed in normoglycemic animals. These studies led
to the hypothesis that the inhibition of insulin secretion
plays a critical role in the hyperglycemia. The present
study attempts to test this hypothesis in a series of 3 ex-
periments. First, we used naturally developed diabetic
monkeys who required insulin treatment because their
insulin secretory function was greatly diminished. Our
data clearly demonstrate that xylazine not only pro-
duced profound hyperglycemia in the normoglycemic
monkeys, but also in the diabetic animals (Figure 2).
Secondly, blood insulin, glucagon, and GLP-1 exhibited
no significant changes during the xylazine-induced
hyperglycemic period (Figure 2). Thirdly, xylazine still
caused hyperglycemia (Figure 3) and decreased glucose
uptake (M rate, Figure 4) during hyperinsulinemic-
euglycemic clamp. These results are consistent with
those reported in foals that insulin was not significantly
changed during xylazine-produced hyperglycemia [36].
However, xylazine-induced hyperglycemia in rats, sheep,
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secretion [35,37-41], while a significant rise in plasma
insulin levels occurs in horses [42]. These inconsistent
results may be due to different animal species used. Our
results suggest that xylazine-induced hyperglycemia re-
sults from the decrease of tissue sensitivity to insulin,
which leads to the reduction of tissue glucose uptake
and utilization.
Xylazine is an analogue of the α2-adrenergic agonist
clonidine. The effects of activation of α2-adrenoceptors
on blood glucagon are inconsistent and whether the
hyperglycemic effect of xylazine involves glucagon is
not clear [37,43]. Previous studies in rats showed that
xylazine significantly increased blood glucagon, which
was not affected by the α2-adrenergic antagonist yohim-
bine [1,12,35]. The unchanged glucagon level found in
our present study is consistent with the results previ-
ously reported in dogs [11]. Glucagon thus seems not so
critical for xylazine-induced hyperglycemia at least in
NHPs in this study. Furthermore, blood GLP-1 was also
not altered after xylazine administration in the present
study. Therefore, it is possible that the cause of xylazine-
induced hyperglycemia results from stimulation of α2-
adrenoceptors and then modifying other stress hormones,
such as ACTH and GH, which were not measured in our
study. However, xylazine has been reported to increase the
release of ACTH and GH in cattle and dogs [3,39].
It is unclear whether xylazine itself could increase
hepatic glucose production (glycogenolysis and gluco-
neogenesis) and then cause hyperglycemia. However, as
xylazine-induced hyperglycemia observed in the present
study was conducted in fasted monkeys which had
reduced glycogen stores [44], the contribution of glyco-
genolysis to the hyperglycemia was very unlikely, espe-
cially in fasted insulin-dependent diabetic monkeys. In
addition, the level of blood glucagon (the stimulating
hormone of glycogenolysis and gluconeogenesis) was
not increased in the presence of xylazine (Figure 2C).
Therefore, xylazine-induced hyperglycemia was unlikely
via an increase in hepatic glucose production.
Compared with the insulin-dependent diabetic mon-
keys, the decline of xylazine-induced hyperglycemia
was faster and blood glucose returned to the pre-
xylazine level within 90 min in normoglycemic mon-
keys (Figure 2A). In contrast, blood glucose remained
elevated during the entire observation period of 120 min
in the diabetic monkeys. The specific α2-adrenoceptor
antagonist yohimbine had to be given in 4 out of 5 insulin
dependent diabetic monkeys to decrease their blood glu-
cose to the pre-xylazine level for animal safety reason.
These results suggest that xylazine-induced hyperglycemia
is mediated, at least partially, via stimulation of α2-
adrenoceptors. Lattermann and colleagues reported that
blood glucose concentrations were significantly increasedin patients during and after lower abdominal surgery
[45]. However, compared with control patients (saline),
intraoperative glucose plasma concentrations were even
higher in the patients who received clonidine (1 μg/kg)
30 min before induction of general anesthesia. The ad-
verse effects of hyperglycemia can be reflected in animal
models of myocardial infarction [46] and in patients
after acute myocardial infarction [47], stroke [48], and
cardiac surgery [49]. Therefore, great care should be
taken to avoid using an agent which causes hypergly-
cemia and influences outcome.
Due to the difficulty of obtaining traditional illicit drugs,
consumption in drug abusers is turning towards less
restricted compounds. Xylazine, the veterinary sedative
anesthetic, was confirmed as the anesthetic substance used
in Puerto Rico by testing exchanged needles in 29 sites in
11 municipalities [22]. Xylazine used as adulterants in her-
oin was also found in drug related deaths in Philadelphia,
Pennsylvania [20,50]. An 18-year-old man after inhaling
xylazine showed chills and dizziness followed by sweating,
gait instability, palpitations and syncope with bradycardia
and hypotension. More cases of toxicity caused by xylazine
consumption have been documented in humans, occa-
sionally resulting in death [18,20,28]. Xylazine users could
become apneic and require intubation and mechanical
ventilation. Two critical issues about chronic use of
xylazine are the physical dependence and the noticeable
open skin ulcers [6]. These ulcers are referred to as ab-
scesses and are a serious health concern. The pain caused
by the ulcers promotes further injections of xylazine be-
cause of its sedative/anesthetic effects. These open skin
ulcers emit a strong odor, ooze, and in severe cases limit
the mobility of the extremities with a possibility of am-
putation [25]. In xylazine abusers (generally male with a
mean age of 30 years) 35% have skin lesions, which
leads to more social exclusion. It is unclear whether the
skin ulcers result from the hyperglycemic effect of
xylazine in abusers, because extremity infection in diabetic
patients is common and severe, sometimes difficult to
cure [22]. More experiments are thus required to elucidate
how xylazine induces hyperglycemia at the cellular and
molecular levels, which may have clinical relevance.
Conclusions
In conclusion, the anesthetic xylazine can cause acute
hyperglycemia with no significant alterations of blood
insulin, glucagon, and GLP-1 in normoglycemic and
insulin-dependent diabetic non-human primates. Such
hyperglycemia is most likely via xylazine stimulation of
α2-adrenoceptors and subsequent reduction of tissue
sensitivity to insulin and glucose uptake.
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